Bifeprunox - Lundbeck A/S/Solvay
Alternative Names: DU-127090Latest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator Solvay
- Developer Lundbeck A/S; Solvay
- Class Antipsychotics; Benzoxazoles; Piperazines; Small molecules
- Mechanism of Action 5-HT1A serotonin receptor agonists; Dopamine D2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bipolar disorders; Parkinson's disease; Schizophrenia
Most Recent Events
- 30 Jul 2009 Discontinued - Phase-III for Schizophrenia in European Union (PO)
- 30 Jul 2009 Discontinued - Preregistration for Schizophrenia in USA (PO)
- 05 Mar 2008 Discontinued - Phase-II for Parkinson's disease in USA (PO)